Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.555 USD | +0.41% | -35.26% | -16.49% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.49% | 245M | |
+11.86% | 225B | |
+10.74% | 186B | |
+13.12% | 135B | |
+25.42% | 107B | |
+0.76% | 63.56B | |
+6.74% | 51.32B | |
+12.03% | 51.04B | |
+8.53% | 43.3B | |
+4.93% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wolfe Research Starts NeuroPace at Outperform With $13 Price Target